CN100469776C - 白内障和其它眼病发展的改善 - Google Patents

白内障和其它眼病发展的改善 Download PDF

Info

Publication number
CN100469776C
CN100469776C CNB038112213A CN03811221A CN100469776C CN 100469776 C CN100469776 C CN 100469776C CN B038112213 A CNB038112213 A CN B038112213A CN 03811221 A CN03811221 A CN 03811221A CN 100469776 C CN100469776 C CN 100469776C
Authority
CN
China
Prior art keywords
alkyl
composition
compound
methyl
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038112213A
Other languages
English (en)
Chinese (zh)
Other versions
CN1653125A (zh
Inventor
威廉·L·马蒂尔
甘希亚姆·帕蒂尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Colby Pharmaceutical Co
Original Assignee
OTHERA HOLDINGS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OTHERA HOLDINGS Inc filed Critical OTHERA HOLDINGS Inc
Publication of CN1653125A publication Critical patent/CN1653125A/zh
Application granted granted Critical
Publication of CN100469776C publication Critical patent/CN100469776C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB038112213A 2002-05-17 2003-05-19 白内障和其它眼病发展的改善 Expired - Fee Related CN100469776C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38128702P 2002-05-17 2002-05-17
US60/381,287 2002-05-17

Publications (2)

Publication Number Publication Date
CN1653125A CN1653125A (zh) 2005-08-10
CN100469776C true CN100469776C (zh) 2009-03-18

Family

ID=29550095

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038112213A Expired - Fee Related CN100469776C (zh) 2002-05-17 2003-05-19 白内障和其它眼病发展的改善

Country Status (13)

Country Link
US (3) US7442711B2 (https=)
EP (1) EP1507826A4 (https=)
JP (1) JP4615309B2 (https=)
KR (1) KR20060013632A (https=)
CN (1) CN100469776C (https=)
AU (1) AU2003243282B2 (https=)
BR (1) BR0310057A (https=)
CA (1) CA2484512C (https=)
IL (1) IL164639A (https=)
MX (1) MXPA04011416A (https=)
NO (1) NO20045483L (https=)
WO (1) WO2003096991A2 (https=)
ZA (1) ZA200408449B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060013632A (ko) * 2002-05-17 2006-02-13 오쎄라 파마슈티걸즈, 인크. 백내장 및 다른 안질환 발병의 개선
US20040057983A1 (en) 2002-09-25 2004-03-25 David Schmidt Biomolecular wearable apparatus
AU2003300471A1 (en) * 2003-01-03 2004-08-10 Eric F. Bernstein Methods for treating ocular diseases
US7825134B2 (en) * 2003-05-19 2010-11-02 Othera Holding, Inc. Amelioration of cataracts, macular degeneration and other ophthalmic diseases
US7589107B2 (en) * 2003-05-19 2009-09-15 Othera Holding, Inc. Amelioration of vitrectomy-induced cataracts
EP1689354A4 (en) * 2003-11-20 2010-07-14 Othera Holding Inc REDUCTION OF CATARACTS, MACULAR GENERATION AND OTHER EYES DISEASES
CA2546042A1 (en) * 2003-11-20 2005-06-09 Othera Pharmaceuticals, Inc. Amelioration of macular degeneration and other ophthalmic diseases
US20080312283A1 (en) * 2005-05-26 2008-12-18 Othera Pharmaceuticals, Inc. Use of Hydroxylamine Derivates for Inhibiting Vitrectomy-Induced Cataracts
US20070197599A1 (en) * 2006-02-02 2007-08-23 Matier William L Hydroxylamines and derivatives as anti-angiogenic agents
US20070203190A1 (en) * 2006-02-22 2007-08-30 Ghanshyam Patil Hydroxylamines and derivatives for the inhibition of complement activation
US20070197593A1 (en) * 2006-02-22 2007-08-23 Matier William L Hydroxylamines and derivatives for treatment of inflammatory conditions of the liver
CA2678363A1 (en) * 2007-02-16 2008-08-21 Othera Holding, Inc. Drug resistance reversal in neoplastic disease
BRPI0807571A2 (pt) 2007-02-22 2014-07-01 Othera Holding Inc Compostos de hidroxilamina e métodos de seu uso
EP2217589A4 (en) * 2007-11-28 2012-02-22 Revision Therapeutics Inc MODULATORS OF OCULAR OXIDATIVE STRESS
US8602961B2 (en) 2008-05-15 2013-12-10 Lifewave Products Llc Apparatus and method of stimulating elevation of glutathione levels in a subject
WO2011059474A1 (en) 2009-10-30 2011-05-19 Nestec S.A. Methods for maintaining eye health and ameliorating opthalmic maladies in canines
US8778969B2 (en) 2009-11-07 2014-07-15 Peter H Proctor Nitrone, nitroso, and nitroxide spintraps and spin labels and their hydroxylamines
EP2397474A1 (de) * 2010-06-17 2011-12-21 Construction Research & Technology GmbH 2-Oxo-1,3-dioxolan-4-carbonsäureester, ihre Herstellung und Verwendung
US9012647B2 (en) 2011-04-07 2015-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide modified non-steroidal anti-inflammatory compounds and uses thereof in the treatment and prevention of diseases or disorders
EP2514800B2 (de) 2011-04-21 2018-03-07 Merck Patent GmbH Verbindungen und flüssigkristallines Medium
JP6072067B2 (ja) * 2011-12-22 2017-02-01 コンストラクション リサーチ アンド テクノロジー ゲーエムベーハーＣｏｎｓｔｒｕｃｔｉｏｎ Ｒｅｓｅａｒｃｈ ＆ Ｔｅｃｈｎｏｌｏｇｙ ＧｍｂＨ ２−オキソ−１，３−ジオキソラン−４−カルボキサミド、その製造方法および使用
CN102584683B (zh) * 2012-02-29 2014-12-24 中国人民解放军第四军医大学 Tempol类衍生物的合成及辐射防护作用
EP2818465A1 (en) * 2013-06-26 2014-12-31 Construction Research & Technology GmbH 2-Oxo-1,3-dioxolane-4-acyl halides, their preparation and use
US9314457B2 (en) 2014-06-19 2016-04-19 The University Of Utah Research Foundation Methods of treating and preventing vascular instability diseases
CN116963727A (zh) * 2020-11-13 2023-10-27 普莱克斯医药公司 用于治疗眼部病症的药剂
PL441664A1 (pl) * 2022-07-07 2024-01-08 Uniwersytet Warszawski Nitroksylowa pochodna polifenolu, sposoby jej wytwarzania oraz jej zastosowanie

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145893A (en) * 1989-03-21 1992-09-08 Ciba-Geigy Corporation Non-migrating 1-hydrocarbyloxy hindered amine derivatives as polymer stabilizers
US6001853A (en) * 1996-01-26 1999-12-14 The United States Of America As Represented By The Department Of Health And Human Services Hydroxylamine compositions for the prevention or retardation of cataracts

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3936456A (en) 1972-03-24 1976-02-03 Ciby-Geigy Corporation Substituted piperazine dione oxyls and hydroxides and polymer compositions stabilized thereby
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
NL188266C (nl) 1975-07-29 1992-05-18 Merck & Co Inc Werkwijze ter bereiding van een oogheelkundig inplantaat.
US4287175A (en) 1978-06-22 1981-09-01 Merck & Co., Inc. Contact lens wetting agents
JPS5899449A (ja) 1981-12-09 1983-06-13 Sanyo Chem Ind Ltd カチオン性ビニルモノマ−の安定化法
US4404302A (en) 1982-05-27 1983-09-13 Ferro Corporation Acylated hindered hexahydropyrimidines and their use as light stabilizing agents
US4590231A (en) 1983-10-11 1986-05-20 Ciba-Geigy Corporation Polyolefin compositions stabilized against degradation using hydroxylamine derivatives
EP0163696B1 (en) 1983-11-14 1992-11-25 Columbia Laboratories, Inc. Use of a bioadhesive
US5225196A (en) 1983-11-14 1993-07-06 Columbia Laboratories, Inc. Bioadhesive compositions and methods of treatment therewith
US4983392A (en) 1983-11-14 1991-01-08 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
EP0157738B1 (de) 1984-03-22 1989-04-19 Ciba-Geigy Ag Verfahren zur Herstellung von Nitroxylen sterisch gehinderter Amine
US4691015A (en) 1984-07-23 1987-09-01 Ciba-Geigy Corporation Hydroxylamines derived from hindered amines
US5209927A (en) 1985-01-23 1993-05-11 Alcon Laboratories, Inc. Ophthalmic solution
US4668699A (en) 1985-08-05 1987-05-26 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
JPS6385547A (ja) 1986-09-29 1988-04-16 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
US4818537A (en) 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
FR2608045B1 (fr) 1986-12-12 1990-03-02 Chauvin Laboratoires Utilisation d'inhibiteurs de xanthine- oxydase, de piegeurs de radicaux libres oxygenes et de chelateurs du fer pour la fabrication d'une composition pharmaceutique destinee au traitement du glaucome et compositions pharmaceutiques destinees au traitement du glaucome
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
EP0309401B2 (en) 1987-09-21 2002-06-05 Ciba Specialty Chemicals Holding Inc. Stabilization of coatings with N-hydroxy hindered amines
EP0309400B1 (en) 1987-09-21 1994-03-02 Ciba-Geigy Ag N-acyloxy hindered amine stabilizers
DE3801790A1 (de) 1988-01-22 1989-07-27 Resart Ihm Ag Kunststoffmaterial mit hoher uv-durchlaessigkeit, verfahren zu dessen herstellung und dessen verwendung
DE58907159D1 (de) 1988-06-14 1994-04-14 Ciba Geigy Verfahren zum fotochemischen Stabilisieren von ungefärbten und gefärbten Polypropylenfasern.
US5073278A (en) 1988-07-18 1991-12-17 Ciba-Geigy Corporation Lubricant composition
US5004770A (en) 1988-10-19 1991-04-02 Ciba-Geigy Corporation Polymeric substrates stabilized with N-substituted hindered amines
US4927891A (en) 1988-11-23 1990-05-22 Pennwalt Corporation Polymer bound light stabilizer coating resins
US5030243A (en) 1989-01-05 1991-07-09 Ciba-Geigy Corporation Process for the photochemical stabilization of undyed and dyeable artificial leather with a sterically hindered amine
DE4000551A1 (de) 1989-01-13 1990-07-19 Ciba Geigy Ag Verfahren zum fotochemischen stabilisieren von gefaerbter wolle
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
JPH0331342A (ja) 1989-06-28 1991-02-12 Mitsubishi Petrochem Co Ltd ポリオレフィン樹脂組成物
EP0432089B1 (de) 1989-11-08 1996-09-04 Ciba-Geigy Ag Schmierstoffzusammensetzungen
DK0787492T3 (da) 1990-03-16 2004-02-02 Us Secretary United States Dep Anvendelse af nitroxider og oxazolidiner til beskyttelse mod ioniserende stråling og oxidativt stress
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
EP0459148B1 (en) 1990-05-29 1996-01-03 Ocular Research Of Boston Inc. Dry eye treatment composition
EP0467850B1 (en) 1990-07-20 1995-09-06 Ciba-Geigy Ag Stabilized monomer compositions
KR100193146B1 (ko) * 1990-07-20 1999-06-15 월터 클리웨인, 한스-피터 위트린 안정화된 단량체 조성물
US5290888A (en) 1990-07-20 1994-03-01 Ciba-Geigy Corporation Process for stabilizing ethylenically unsaturated compounds and stabilized monomer compositions
JPH04166930A (ja) 1990-10-31 1992-06-12 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US5475013A (en) 1990-11-19 1995-12-12 Monsanto Company Retroviral protease inhibitors
FR2670517B1 (fr) 1990-12-13 1993-04-09 Normandie Const Meca Element de franchissement pour le franchissement d'obstacles.
CA2058823A1 (en) 1991-01-08 1992-07-09 Rolf Schumacher Lubricant compositions
JP2681424B2 (ja) 1991-04-12 1997-11-26 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料
IT1246779B (it) 1991-04-12 1994-11-26 Ciba Geigy Spa Composti piperidinici atti all'impiego come stabilizzanti per materiali organici.
US5399473A (en) 1991-04-12 1995-03-21 Fuji Photo Film Company, Ltd. Silver halide color photographic material
ES2101994T3 (es) 1992-04-08 1997-07-16 Ciba Geigy Ag Antioxidantes liquidos como estabilizadores.
DE4327297B4 (de) 1992-08-17 2007-05-24 Clariant Finance (Bvi) Ltd. Verwendung von Piperidinverbindungen
TW237471B (https=) 1992-09-03 1995-01-01 Ciba Geigy
JPH06172592A (ja) 1992-12-09 1994-06-21 Sumitomo Chem Co Ltd カーボンブラック含有ポリオレフィン系樹脂組成物
US5707643A (en) 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
CH688878B5 (de) 1993-04-06 1998-11-13 Ciba Geigy Ag Handelsformen von sterisch gehindertem Amin und deren Verwendung.
IT1270975B (it) 1993-06-03 1997-05-26 Ciba Geigy Spa Composti piperidin-triazinici atti all'impiego come stabilizzanti allaluce, al calore e alla ossidazione per materiali organici
DE4320444A1 (de) 1993-06-21 1994-12-22 Agfa Gevaert Ag Farbfotografisches Aufzeichnungsmaterial
IT1264946B1 (it) 1993-07-16 1996-10-17 Ciba Geigy Spa Derivati del 2,2,6,6-tetrametil-4-piperidinolo utili come stabilizzanti alla luce ed all'ossidazione per materiali organici.
IT1264817B1 (it) 1993-07-28 1996-10-10 Ciba Geigy Spa Derivati di polialchil-4-piperidinoli atti all'impderivati di polialchil-4-piperidinoli atti all'impiego come stabilizzanti per materiali organici iego come stabilizzanti per materiali organici
EP0638616A1 (de) 1993-08-13 1995-02-15 Ciba-Geigy Ag Pigmentsalze
CA2131047A1 (en) 1993-09-01 1995-03-02 Takashi Sanada Thermoplastic resin composition
GB9318846D0 (en) 1993-09-10 1993-10-27 Sandoz Ltd Improvements in or relating to organic compounds
TW327185B (en) 1993-09-20 1998-02-21 Ciba Sc Holding Ag Liquid antioxidants
WO1995017900A1 (en) 1993-12-30 1995-07-06 Arcturus Pharmaceutical Corporation Methods for the treatment of the central nervous system or eye involving pathogenic oxidation pathways
DE59505941D1 (de) 1994-01-19 1999-06-24 Ciba Geigy Ag Stabilisieren von Leder gegen thermische und photochemische Zersetzung
US5466233A (en) 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
DE69425287T2 (de) 1994-11-15 2001-03-15 Moreno Paolini N-hydroxypiperidine als superoxid-radikalfänger
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5518732A (en) 1995-02-14 1996-05-21 Chiron Vision, Inc. Bio-erodible ophthalmic shield
IT1273607B (it) 1995-04-26 1997-07-08 Ciba Geigy Spa Combinazione di stabilizzanti per polimeri sintetici organici
US5699182A (en) 1995-05-25 1997-12-16 Xytronyx, Inc. Light fatigue resistant photochromic formulations
TW416970B (en) 1995-05-31 2001-01-01 Ciba Sc Holding Ag Carrier-bound light stabilizers and antioxidants as fillers and stabilizers
US5718922A (en) 1995-05-31 1998-02-17 Schepens Eye Research Institute, Inc. Intravitreal microsphere drug delivery and method of preparation
US6469057B1 (en) * 1995-06-02 2002-10-22 Mcw Research Foundation, Inc. Methods for in vivo reduction of free radical levels and compositions useful therefor
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
DE19530468A1 (de) 1995-08-18 1997-02-20 Sandoz Ag Verwendung von Piperidinverbindungen
JPH0952975A (ja) 1995-08-18 1997-02-25 Clariant Internatl Ltd 顔料の安定化方法及びこの方法に用いる組成物
EP0761466B1 (en) 1995-08-30 1999-08-04 Eastman Kodak Company Stabilised dye-donor element for use in thermal dye transfer
US5821374A (en) 1995-11-21 1998-10-13 Hoffmann-La Roche Inc. Process for the oxidation of alcohols
GB9607565D0 (en) 1996-04-12 1996-06-12 Clariant Int Ltd Stabilizer composition
DE69705040T2 (de) 1996-04-12 2001-09-20 Clariant Finance (Bvi) Ltd., Road Town Stabilisation von polyolefinen
DE19618197A1 (de) 1996-05-07 1997-11-13 Hoechst Ag Neue sterisch gehinderte Piperidinderivate als Lichtschutzmittel für Polymere
JPH1045777A (ja) 1996-07-29 1998-02-17 Sakai Chem Ind Co Ltd 新規な有機リン化合物及びその用途
JPH1045778A (ja) 1996-07-29 1998-02-17 Sakai Chem Ind Co Ltd 新規なヒンダードアミン塩及びその用途
DE69722441T2 (de) 1996-12-19 2004-08-19 Exxonmobil Chemical Patents Inc., Baytown Verfahren zur schmelverarbeitung von amin enthaltendem polyethylen
KR20000069479A (ko) 1996-12-20 2000-11-25 시바 스폐셜티 케미칼스 홀딩 인코포레이티드 고형 기재 재료상에 고정된 에스테르 교환 반응 촉매
EP0895474A4 (en) * 1997-01-29 2003-03-05 A Glenn Braswell LIQUID EYE DROP COMPOSITION
US5981584A (en) 1997-02-06 1999-11-09 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
JPH10220381A (ja) 1997-02-07 1998-08-18 Matsushita Refrig Co Ltd 密閉型圧縮機
JPH10219140A (ja) 1997-02-07 1998-08-18 Nippon Nsc Ltd 耐候性塗料用樹脂エマルション
DE19816681A1 (de) 1997-04-18 1998-10-22 Ciba Geigy Ag Azidhaltige Stabilisatoren
IT1291599B1 (it) 1997-04-18 1999-01-11 Great Lakes Chemical Italia Composti appartenenti alla classe delle enammine e loro utilizzo come antiossidanti per polimeri organici
IT1302988B1 (it) 1997-05-08 2000-10-18 Great Lakes Chemical Italia Polimeri organici stabilizzati alla luce
RU2223985C2 (ru) 1997-07-23 2004-02-20 Циба Спешиалти Кемикалз Холдинг Инк. Ингибирование пожелтения целлюлозы и бумаги с использованием нитроксидов и других совместно вводимых добавок
DE19735255B4 (de) 1997-08-14 2007-08-23 Clariant Produkte (Deutschland) Gmbh Synergistisches Stabilisatorgemisch auf Basis von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen und dessen Verwendung
US5902598A (en) 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
FR2773165B1 (fr) 1997-12-26 2001-06-08 Rhodia Chimie Sa Stabilisation des moules en elastomere silicone
FR2773320B1 (fr) 1998-01-05 2000-03-03 Optisinvest Dispositif pour le transfert intraoculaire de produits actifs par iontophorese
DE19804910A1 (de) 1998-02-07 1999-08-12 Clariant Gmbh Polyolefin-Formmasse zur Herstellung von kalandrierten Folien/Platten
IT1298452B1 (it) 1998-02-26 2000-01-10 Great Lakes Chemical Italia Composizioni fotocromatiche dotate di resistenza a fatica alla luce ed articoli fotocromatici che le contengono
TWI224995B (en) 1998-03-19 2004-12-11 Ciba Sc Holding Ag Stabilization of wood substrates
US6149925A (en) * 1998-11-05 2000-11-21 Color Access, Inc. Topical compositions for enhancing glutathione production
AU3119100A (en) 1998-12-17 2000-07-03 Alcon Laboratories, Inc. Methods for the prevention and treatment of post-surgical complications
US6410045B1 (en) 1999-02-22 2002-06-25 Clyde Lewis Schultz Drug delivery system for antiglaucomatous medication
EP1156809B1 (en) 1999-03-01 2005-12-07 Vista Scientific LLC Mucin containing ophthalmic preparations
US6429194B1 (en) 1999-03-01 2002-08-06 Vista Scientific Llc Mucin containing ophthalmic preparation
JP3527435B2 (ja) 1999-05-21 2004-05-17 ユニ・チャーム株式会社 使い捨ておむつ
TW514581B (en) 1999-09-02 2002-12-21 Ciba Sc Holding Ag A method of protecting wood against light-induced degradation by treatment with an impregnation which penetrates the surface of the wood
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US20030109566A1 (en) 2000-06-29 2003-06-12 Tomiya Mano Remedial agent for optic nerve disease and the like
IT1320080B1 (it) 2000-10-25 2003-11-18 Giuliani Spa Composizione per uso farmaceutico o dietetico.
JP4594727B2 (ja) * 2002-05-02 2010-12-08 チバ ホールディング インコーポレーテッド 安定化ボディケア製品、家庭用品、織物材料及び織物
KR20060013632A (ko) 2002-05-17 2006-02-13 오쎄라 파마슈티걸즈, 인크. 백내장 및 다른 안질환 발병의 개선
US7825134B2 (en) 2003-05-19 2010-11-02 Othera Holding, Inc. Amelioration of cataracts, macular degeneration and other ophthalmic diseases
JP4288302B1 (ja) 2008-01-18 2009-07-01 トモデータサービス有限会社 位置検出装置および位置検出プログラム並びに施設図面データ

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145893A (en) * 1989-03-21 1992-09-08 Ciba-Geigy Corporation Non-migrating 1-hydrocarbyloxy hindered amine derivatives as polymer stabilizers
US6001853A (en) * 1996-01-26 1999-12-14 The United States Of America As Represented By The Department Of Health And Human Services Hydroxylamine compositions for the prevention or retardation of cataracts

Also Published As

Publication number Publication date
US20040002461A1 (en) 2004-01-01
CN1653125A (zh) 2005-08-10
EP1507826A2 (en) 2005-02-23
WO2003096991A3 (en) 2004-02-26
US7442711B2 (en) 2008-10-28
IL164639A (en) 2012-02-29
EP1507826A4 (en) 2007-11-07
AU2003243282A1 (en) 2003-12-02
CA2484512C (en) 2013-04-16
BR0310057A (pt) 2007-04-10
US20130131052A1 (en) 2013-05-23
JP4615309B2 (ja) 2011-01-19
IL164639A0 (en) 2005-12-18
CA2484512A1 (en) 2003-11-27
NO20045483L (no) 2004-12-16
ZA200408449B (en) 2007-09-26
WO2003096991A2 (en) 2003-11-27
AU2003243282B2 (en) 2008-05-01
JP2005527605A (ja) 2005-09-15
US20080274983A1 (en) 2008-11-06
MXPA04011416A (es) 2005-09-30
KR20060013632A (ko) 2006-02-13
US8383648B2 (en) 2013-02-26

Similar Documents

Publication Publication Date Title
CN100469776C (zh) 白内障和其它眼病发展的改善
US7153883B2 (en) Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
JP2013531063A (ja) 二官能基Ｒｈｏキナーゼ阻害化合物、組成物およびその使用
JP2013532689A (ja) プロドラッグ形態のキナーゼ阻害剤化合物を使用して眼疾患を治療する方法
AU2008218783A1 (en) Hydroxylamine compounds and methods of their use
EP3197880B1 (de) Substituierte oxopyridin-derivate mit anti-inflammatorischer und anti-thrombotischer wirkung
CA2546053A1 (en) Amelioration of cataracts, macular degeneration and other ophthalmic diseases
US7825134B2 (en) Amelioration of cataracts, macular degeneration and other ophthalmic diseases
US20170065602A1 (en) Compounds with trpv4 activity, compositions and associated methods thereof
CN1964711A (zh) 眼睛选择性药物及前体药物
WO1997000068A1 (en) Corneal clouding inhibitor
ZA200604402B (en) Amelioration of cataracts, macular degeneration and other ophthalmic diseases
WO2024211621A1 (en) Lats kinase inhibitor to treat retinal degeneration
JP2008024699A (ja) フマル酸誘導体を有効成分として含む角結膜障害の予防または治療剤
KR20030007575A (ko) 안압 강하제

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: COLBY PHARMACEUTICAL COMPANY

Free format text: FORMER OWNER: OTHERA HOLDINGS INC.

Effective date: 20130522

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20130522

Address after: American California

Patentee after: Colby Pharmaceutical Company

Address before: Delaware

Patentee before: Othera Holdings Inc.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090318

Termination date: 20140519